Project Grant R43TR005938
Award Date 8/1/25
Completion Date 7/31/26
Dollars Obligated $380K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02130, USA
Similar Awards
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $299,995 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Nanite Inc., a small disadvantaged business in Massachusetts. The grant will fund the development of computationally-designed polymer-based delivery vehicles for mRNA payloads to treat cystic fibrosis (CF), a debilitating genetic disorder affecting the lungs. The project aims to leverage computational modeling and high-throughput polymer...
- The Project Grant award of $564,121 from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) will support research to develop peptide surface-functionalized lipid nanoparticles (PepLNPs) for pulmonary delivery that can reach airway basal cells and use base editing technology to correct specific CFTR gene mutations associated with cystic fibrosis. The goal is to achieve permanent correction of lung disease in cystic fibrosis patients through one-time,...
- This federal Project Grant award of $441,375.00, provided by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop and optimize a dual adeno-associated virus (AAV) system with intein technology to deliver full-length, functional cystic fibrosis transmembrane conductance regulator (CFTR) protein to airway epithelial cells of cystic fibrosis (CF) patients. The goal is to restore CFTR function in CF patients, particularly those...
- This federal Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), provides $350,000 in funding to Cisterna Biologics, Inc. to develop a novel mRNA production and purification process. The key objectives are to: Optimize psychrophilic (cold-adapted) RNA polymerases and synthetic promoters to minimize contaminants in mRNA synthesis, improving safety and efficacy for therapeutic use. Implement...
- This $419,398 Project Grant award, funded by the National Center for Advancing Translational Sciences (NCATS) CFDA Program 93.350, is supporting research to accelerate the development and delivery of oligonucleotide therapeutics (ONTs). The project aims to address the key barrier of biological membrane permeability that limits the ability of large, charged ONT molecules to reach their therapeutic targets within cells. The research at the University of California, Irvine will explore novel...
- This $3,757,391 Project Grant award from the U.S. Defense Health Agency under the Department of Defense's Military Medical Research and Development program (CFDA 12.420) supports the development of a field-use therapeutic for pulmonary injuries from trauma or chemical exposure. The awardee, Ceria Therapeutics Inc., is a for-profit biotechnology company that develops novel therapeutics targeting inflammation and oxidative stress. The funding will enable Ceria Therapeutics to advance its...
- The University of Delaware received a $427,811 Project Grant award from the National Center for Advancing Translational Sciences (NCATS), CFDA 93.350, to develop a "Total Inhalable Deposition in an Actuated Lung" (TIDAL) model. This multiscale dynamic preclinical tool will measure the spatial deposition of aerosol therapeutics and vaccines across the lung as a function of patient-specific breathing, anatomy, and disease state. The goal is to address a major bottleneck in predicting how...
- The National Center for Advancing Translational Sciences (NCATS), through its CFDA 93.350 Federal Grant Program, awarded a $294,541 Project Grant to Cellular Vehicles Inc. on June 1, 2024. The purpose of this award is to develop an automated system for producing and delivering cell-laden hydrogel therapies. The project aims to create a novel, standardized process for formulating, encapsulating, and directly injecting cell-laden hydrogels into diseased tissues. This is intended to improve the...
- This Project Grant award of $235,500 from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) supports the development of a microscale robotic system to facilitate adeno-associated virus serotype 4 (AAV4)-mediated gene delivery of the cystic fibrosis transmembrane conductance regulator (CFTR) to the small airway epithelium in cystic fibrosis patients. The...
- This Project Grant award of $629,319.00 from the National Heart Lung and Blood Institute (CFDA #93.837 Cardiovascular Diseases Research) supports research by Emory University to investigate cellular mechanisms for overcoming refractory cystic fibrosis defects. The research aims to identify ribosomal proteins that can partially rescue the synthesis and assembly of cystic fibrosis transmembrane conductance regulator (CFTR) protein variants with premature termination codons, which are associated...